| Dr George Toufic Nahhas, MD | |
|
2881 Monroe St, Suite 100, Dearborn, MI 48124-2847 | |
| (313) 562-3232 | |
| (313) 563-3330 |
| Full Name | Dr George Toufic Nahhas |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 36 Years |
| Location | 2881 Monroe St, Dearborn, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427084805 | NPI | - | NPPES |
| 060053916 | Other | MI | MEDICARE RR |
| P94852 | Other | MI | BLUECARENETWORK |
| 0Q26305004 | Other | MI | BLUECROSSBLUESHIELD OF MI |
| 3470691 | Medicaid | MI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital - Dearborn | Dearborn, MI | Hospital |
| Beaumont Hospital - Taylor | Taylor, MI | Hospital |
| Beaumont Hospital - Trenton | Trenton, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ehk Endovascular Pllc | 0648449272 | 10 |
| Venocure, Pllc | 9234203068 | 2 |
News Archive
A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that Phase 1 data of perifosine (KRX-0401) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
People with addictions to stimulants tend to choose instant gratification or a smaller but sooner reward over a future benefit, even if the future reward is greater. Reduced value of a future reward, called "delay discounting" by neuroscientists, is the major challenge for treatment of addiction. A new study in the February 2011 (Vol. 69, Issue 3) Biological Psychiatry appears to present a strategy for increasing the value of future rewards in the minds of addicts.
A condition of publishing in the Open Access life sciences journal F1000Research is that authors make the data underlying their findings publicly available alongside the article. Openly sharing data is an important step in helping tackle issues around the lack of reproducibility of much published research, as well as enabling data reuse.
Vital clues about how the brain erases long term memories have been uncovered by researchers. The study in rats reveals how forgetting can be the result of an active deletion process rather than a failure to remember.
› Verified 4 days ago
| Entity Name | Henry Ford Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134144801 PECOS PAC ID: 0547178311 Enrollment ID: O20031105000139 |
News Archive
A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that Phase 1 data of perifosine (KRX-0401) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
People with addictions to stimulants tend to choose instant gratification or a smaller but sooner reward over a future benefit, even if the future reward is greater. Reduced value of a future reward, called "delay discounting" by neuroscientists, is the major challenge for treatment of addiction. A new study in the February 2011 (Vol. 69, Issue 3) Biological Psychiatry appears to present a strategy for increasing the value of future rewards in the minds of addicts.
A condition of publishing in the Open Access life sciences journal F1000Research is that authors make the data underlying their findings publicly available alongside the article. Openly sharing data is an important step in helping tackle issues around the lack of reproducibility of much published research, as well as enabling data reuse.
Vital clues about how the brain erases long term memories have been uncovered by researchers. The study in rats reveals how forgetting can be the result of an active deletion process rather than a failure to remember.
› Verified 4 days ago
| Entity Name | Venocure, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609041672 PECOS PAC ID: 9234203068 Enrollment ID: O20080728000770 |
News Archive
A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that Phase 1 data of perifosine (KRX-0401) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
People with addictions to stimulants tend to choose instant gratification or a smaller but sooner reward over a future benefit, even if the future reward is greater. Reduced value of a future reward, called "delay discounting" by neuroscientists, is the major challenge for treatment of addiction. A new study in the February 2011 (Vol. 69, Issue 3) Biological Psychiatry appears to present a strategy for increasing the value of future rewards in the minds of addicts.
A condition of publishing in the Open Access life sciences journal F1000Research is that authors make the data underlying their findings publicly available alongside the article. Openly sharing data is an important step in helping tackle issues around the lack of reproducibility of much published research, as well as enabling data reuse.
Vital clues about how the brain erases long term memories have been uncovered by researchers. The study in rats reveals how forgetting can be the result of an active deletion process rather than a failure to remember.
› Verified 4 days ago
| Entity Name | Ehk Endovascular Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477845824 PECOS PAC ID: 0648449272 Enrollment ID: O20110816000217 |
News Archive
A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that Phase 1 data of perifosine (KRX-0401) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
People with addictions to stimulants tend to choose instant gratification or a smaller but sooner reward over a future benefit, even if the future reward is greater. Reduced value of a future reward, called "delay discounting" by neuroscientists, is the major challenge for treatment of addiction. A new study in the February 2011 (Vol. 69, Issue 3) Biological Psychiatry appears to present a strategy for increasing the value of future rewards in the minds of addicts.
A condition of publishing in the Open Access life sciences journal F1000Research is that authors make the data underlying their findings publicly available alongside the article. Openly sharing data is an important step in helping tackle issues around the lack of reproducibility of much published research, as well as enabling data reuse.
Vital clues about how the brain erases long term memories have been uncovered by researchers. The study in rats reveals how forgetting can be the result of an active deletion process rather than a failure to remember.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr George Toufic Nahhas, MD 2881 Monroe St, Suite 100, Dearborn, MI 48124-3475 Ph: (313) 562-3232 | Dr George Toufic Nahhas, MD 2881 Monroe St, Suite 100, Dearborn, MI 48124-2847 Ph: (313) 562-3232 |
News Archive
A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that Phase 1 data of perifosine (KRX-0401) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.
People with addictions to stimulants tend to choose instant gratification or a smaller but sooner reward over a future benefit, even if the future reward is greater. Reduced value of a future reward, called "delay discounting" by neuroscientists, is the major challenge for treatment of addiction. A new study in the February 2011 (Vol. 69, Issue 3) Biological Psychiatry appears to present a strategy for increasing the value of future rewards in the minds of addicts.
A condition of publishing in the Open Access life sciences journal F1000Research is that authors make the data underlying their findings publicly available alongside the article. Openly sharing data is an important step in helping tackle issues around the lack of reproducibility of much published research, as well as enabling data reuse.
Vital clues about how the brain erases long term memories have been uncovered by researchers. The study in rats reveals how forgetting can be the result of an active deletion process rather than a failure to remember.
› Verified 4 days ago
Albagir Mohamed Alarabi, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 | |
Dr. Rama V Thyagarajan, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18181 Oakwood Blvd Ste 101, Medical Office Building, Dearborn, MI 48124 Phone: 313-436-2426 Fax: 313-436-2440 | |
Adeeb M Atassi, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 18181 Oakwood Blvd, Suite Number 208, Dearborn, MI 48124 Phone: 313-563-3332 | |
Mihaela A. Lupu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18181 Oakwood Blvd, Ste 208, Dearborn, MI 48124 Phone: 313-271-5670 Fax: 313-271-1053 | |
Violet Asfour, Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 18100 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-436-2578 | |
Raed Haddad, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9720 Dix, Ste B, Dearborn, MI 48120 Phone: 313-843-1973 Fax: 313-843-1961 | |
Dr. Denise Kirsch, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18101 Oakwood Blvd Ste 101, Dearborn, MI 48124 Phone: 313-436-2426 Fax: 313-436-2440 |